SourceBio International PLC Director's Share Purchase (5291H)
07 April 2022 - 4:10PM
UK Regulatory
TIDMSBI
RNS Number : 5291H
SourceBio International PLC
07 April 2022
SourceBio International plc
("SourceBio", the "Company" or the "Group")
Director's Share Purchase
SourceBio International plc (AIM: SBI), a leading international
provider of integrated state-of-the-art laboratory services and
products , announces that on 6 April 2022, Jay LeCoque, Executive
Chairman, purchased 100,000 Ordinary Shares in the Company at a
price of 129.5 pence per Ordinary Share, representing 0.14% of the
Company's issued share capital.
Jay LeCoque's total shareholding now comprises 2,444,612
Ordinary Shares, representing 3.30% of the Company's issued share
capital.
Contacts:
SourceBio International plc www.sourcebiointernational.com
Jay LeCoque, Executive Chairman Via Walbrook PR
Tony Ratcliffe, Chief Financial Officer
Liberum (Nominated Advisor and Broker) Tel: 020 3100 2000
Richard Lindley / William Hall
Walbrook PR Limited Tel: 020 7933 8780 or sourcebio@walbrookpr.com
Paul McManus / Sam Allen Mob: 07980 541 893 / 07502
558 258
About SourceBio International plc
www.sourcebiointernational.com
SourceBio is a leading international provider of integrated
state-of-the-art laboratory services and products with clients in
the healthcare, clinical, life science research and biopharma
industries, with a focus on improving patient diagnosis, management
and care. Group revenues are derived from four business units:
-- Healthcare Diagnostics - histopathology cancer screening and
clinical diagnostic services for the NHS and private healthcare
providers across the UK and Ireland, including Digital
Pathology
-- Genomics - DNA sequencing services and Precision Medicine
offering for pharmaceutical and biotechnology companies, academia,
contract research organisations (CROs) and other research groups in
the UK, Europe and North America
-- Stability Storage - shelf-life testing services and equipment
for pharmaceutical and biotechnology companies, contract
manufacturers and analytical testing companies from around the
world but primarily in the UK, Ireland and the USA
-- Infectious Disease Testing - a range of COVID-19 testing
services for commercial enterprises, private healthcare groups and
the NHS, including PCR testing under ISO 15189 accreditation.
SourceBio also provides employee testing solutions to industry,
direct to consumer home test kits and venue testing.
More details on Group operations can be found here:
www.sourcebioscience.com
SourceBio International plc (SBI) is listed on the AIM market of
the London Stock Exchange.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name
Jay LeCoque
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial Notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name SourceBio International Plc
b) LEI 213800KY4C9WU7WBW518
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
a) Description of the Ordinary shares of GBP0.0015 each
financial instrument,
type of instrument
Identification code GB00BKSB1674
b) Nature of the transaction Purchase of 100,000 Ordinary Shares
c) Price(s) and volume(s)
Price(s) Volume(s)
129.5 pence 100,000
d) Aggregated information
N/A - single transaction
Volume
Price
e) Date of the transaction 6 April 2022
f) Place of the transaction London Stock Exchange
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSSEFIMEESEFL
(END) Dow Jones Newswires
April 07, 2022 02:10 ET (06:10 GMT)
Sourcebio (LSE:SBI)
Historical Stock Chart
From Nov 2024 to Dec 2024
Sourcebio (LSE:SBI)
Historical Stock Chart
From Dec 2023 to Dec 2024